The Higher Response of Vascular Endothelial Growth Factor and Angiotensin-II to Human Chorionic Gonadotropin in Women with Polycystic Ovary Syndrome

被引:1
|
作者
Qu, Junwei [1 ]
Che, Yena [2 ,3 ]
Xu, Pei [2 ,3 ]
Xia, Yanjie [2 ,3 ]
Wu, Xiaoke [4 ]
Wang, Yong [2 ,3 ]
机构
[1] Jiangsu Canc Hosp & Inst, Dept Gynecol Oncol Surg, Nanjing 210093, Jiangsu, Peoples R China
[2] Nanjing Univ, Translat Med Ctr, Nanjing 210093, Jiangsu, Peoples R China
[3] Nanjing Univ, Jiangsu Key Lab Mol Med, Sch Med, Nanjing 210093, Jiangsu, Peoples R China
[4] Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Dept Obstet & Gynecol, Harbin 150040, Peoples R China
关键词
Polycystic Ovary Syndrome; Vascular Endothelial Growth Factor; Angiotensin-II; Ovarian Hyperstimulation Syndrome;
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: This research investigated the response of vascular active factors, vascular endothelial growth factor (VEGF) and angiotensin-II (AT-II) to ovarian stimulation during 24 hours in patients with polycystic ovary syndrome (PCOS). Materials and Methods: In this clinical trial study, 52 patients with PCOS and 8 control cases were stimulated with human chorionic gonadotropin (HCG) on the 4th to 7th day of the patients' natural or induced menstrual cycles. We measured VEGF and AT-II by radioimmunoassay before the injection (0 hour) and 3, 8, 12, 18 and 24 hours after the stimulation. Results: After ovarian stimulation, there was substantially higher level of VEGF in typical PCOS patients than the other three groups at the 3 hour time point (p<0.05), while there were no significant differences in VEGF at all the other time points among the four groups. As for AT-II, before and at all time points after the ovarian stimulation, it seemed that the AT-II levels in patients' sera with different phenotypes of PCOS by the Rotterdam criteria were all higher than in the control group although the differences were not statistically significant. The level of AT-II in typical PCOS patients was also significantly higher than the other three groups at the 3 hour time point (p<0.05), while no significant differences at all the other time points among the four groups were observed. Conclusion: The response to the stimulation varied among patients with different phenotypes of PCOS according to the Rotterdam criteria. Serum VEGF and AT-II were possible contributors to an increased risk of developing ovarian hyperstimulation syndrome (OHSS) in patients with typical PCOS during the early follicular phase (3 hours) after ovarian stimulation (Registration Number: NCT02265861).
引用
收藏
页码:373 / 378
页数:6
相关论文
共 50 条
  • [1] Human chorionic gonadotropin attenuates the vascular response to angiotensin II
    Hermsteiner, M
    Zoltan, DR
    Künzel, W
    [J]. EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2002, 102 (02): : 148 - 154
  • [2] Human chorionic gonadotropin induces nestin expression in endothelial cells of the ovary via vascular endothelial growth factor signaling
    Takahashi, Noriyuki
    Itoh, Masanori T.
    Ishizuka, Bunpei
    [J]. ENDOCRINOLOGY, 2008, 149 (01) : 253 - 260
  • [3] Expression of vascular endothelial growth factor (VEGF) in the endometrium of women with polycystic ovary syndrome (PCOS)
    Simoes, Ricardo S.
    Sasso, Gisela R.
    Florencio-Silva, Rinaldo
    Maganhin, Carla C.
    Soares-, Jose M., Jr.
    Baracat, Maria Candida P.
    Baracat, Edmund C.
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (12): : 1353 - 1353
  • [4] Vascular endothelial growth factor, polycystic ovary syndrome, and ovarian hyperstimulation syndrome
    Meldrum, DR
    [J]. FERTILITY AND STERILITY, 2002, 78 (06) : 1170 - 1171
  • [5] Ovarian age-related responsiveness to human chorionic gonadotropin in women with polycystic ovary syndrome
    Piltonen, T
    Koivunen, R
    Perheentupa, A
    Morin-Papunen, L
    Ruokonen, A
    Tapanainen, JS
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (08): : 3769 - 3775
  • [6] Human chorionic gonadotropin and vascular endothelial growth factor in normal and complicated pregnancies
    Bartha, JL
    Romero-Carmona, R
    Escobar-Llompart, M
    Paloma-Castro, O
    Comino-Delgado, R
    [J]. OBSTETRICS AND GYNECOLOGY, 2003, 102 (05): : 995 - 999
  • [7] Vascular endothelial growth factor (VEGFA) gene variation in polycystic ovary syndrome in a Tunisian women population
    Ben Salem, Assila
    Megdich, Fatma
    Kacem, Olfa
    Souayeh, Malek
    Ben Ali, Faten Hachani
    Hizem, Sondes
    Janhai, Faouzi
    Ajina, Mounir
    Abu-Elmagd, Muhammad
    Assidi, Mourad
    Al Qahtani, Mohammed H.
    Mahjoub, Touhami
    [J]. BMC GENOMICS, 2015, 17
  • [8] Vascular endothelial growth factor (VEGFA) gene variation in polycystic ovary syndrome in a Tunisian women population
    Assila Ben Salem
    Fatma Megdich
    Olfa Kacem
    Malek Souayeh
    Faten Hachani Ben Ali
    Sondes Hizem
    Faouzi Janhai
    Mounir Ajina
    Muhammad Abu-Elmagd
    Mourad Assidi
    Mohammed H. Al Qahtani
    Touhami Mahjoub
    [J]. BMC Genomics, 17
  • [9] Serum visfatin, vascular endothelial growth factor and matrix metalloproteinase-9 in women with polycystic ovary syndrome
    Dambala, Kalliopi
    Vavilis, Dimitrios
    Bili, Eleni
    Goulis, Dimitrios G.
    Tarlatzis, Basil C.
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2017, 33 (07) : 529 - 533
  • [10] Live birth rate after human chorionic gonadotropin priming in vitro maturation in women with polycystic ovary syndrome
    V. N. A. Ho
    T. D. Pham
    A. H. Le
    T. M. Ho
    L. N. Vuong
    [J]. Journal of Ovarian Research, 11